Bio Essence Corp Announces Strategic Acquisition of MediFlow AI Software Platform

Key Points from the Board of Directors Resolution and Asset Purchase Agreement

• Acquisition of MediFlow AI Platform: Bio Essence Corp (OTCQB: BIOE) has entered into an Asset Purchase Agreement to acquire the MediFlow AI software platform (formerly known as AcuVital) from Zhituo Software Co., Limited, a Hong Kong-based company.
• Equity-Based Consideration: The purchase price for the software platform is USD \$3,500,000, to be paid in restricted common stock of Bio Essence Corp at a valuation approved by its Board of Directors.
• Comprehensive Asset Transfer: The acquisition encompasses all software source and object code, system architecture, databases, algorithms, APIs, documentation, technical frameworks, domain names, trademarks, associated goodwill, and all intellectual property rights related to MediFlow AI.
• Board Approval and Authority: The Board of Directors has approved the transaction and authorized CEO Yin Yan to execute the agreement. All prior actions taken by the company’s executives in relation to this deal have been ratified.
• Closing Timeline: The closing of the transaction is expected to occur within 45 days of signing, subject to satisfaction of all conditions precedent, including Board approval and delivery of necessary documentation.
• Seller Representations and Warranties: Zhituo Software Co., Limited represents that it owns the platform free and clear of liens, and that the assets do not infringe on third-party rights.
• Indemnification and Liability: Seller will indemnify Bio Essence Corp for breaches of representations or covenants and for claims regarding intellectual property infringement. Buyer indemnifies Seller for breaches of the agreement.
• Governing Law: The transaction is governed by the laws of California, with disputes to be resolved in California courts.
• Survival of Representations: Most representations and warranties survive for 18 months post-closing, with certain matters surviving for the relevant statute of limitations period.

Details for Shareholders and Investors

Strategic Rationale and Potential Impact: This acquisition is a significant step in Bio Essence Corp’s growth strategy, marking a major entry into the AI-driven healthcare software market. The MediFlow AI platform, which was previously named AcuVital, appears to be a core asset with potential applications in the rapidly expanding digital health sector.

Equity Dilution: The payment for the acquisition will be made in shares of restricted common stock, equivalent to \$3.5 million. This may result in equity dilution for existing shareholders, depending on the valuation and number of shares issued. The shares will be restricted securities pursuant to U.S. securities laws, limiting immediate resale.

Intellectual Property and Legal Protections: All intellectual property rights, including copyrights, trademarks, trade secrets, and related assets, are being transferred to Bio Essence Corp. The Seller has made strong representations regarding ownership and non-infringement, reducing the risk of future legal disputes.

Tax and Financial Considerations: Each party is responsible for its own taxes arising from the agreement, and the purchase price allocation will comply with tax regulations.

Risk Mitigation: The agreement includes robust indemnification provisions and limitations of liability (excluding fraud and willful misconduct), offering protection to both parties.

Potential Share Price Impact: This acquisition may be price sensitive. The entry into AI healthcare software, combined with the scale of the deal and equity-based consideration, could significantly affect investor sentiment and the company’s future valuation. Investors should consider both the growth prospects and the potential dilution from new share issuance.

Signatories

• Yin Yan, CEO of Bio Essence Corp (Buyer)
• Dangwei Zhu, CEO of Zhituo Software Co., Limited (Seller)
• Other Bio Essence Corp directors: Siyavash Fooladian, William Sluss

Conclusion

The acquisition of the MediFlow AI platform is a major development for Bio Essence Corp, potentially positioning the company for enhanced technological capability and market expansion in digital health. Shareholders are advised to review the details of the transaction, particularly regarding the equity-based payment and strategic implications.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or solicitation to buy or sell any securities. Investors are advised to conduct their own due diligence and consult with their financial advisors before making any investment decisions. The author and publisher are not responsible for any losses incurred from investment decisions based on this article.

View Bio Essence Corp Historical chart here